Report Overview
This is a substantial study based on interviews with 150 pharmaceutical and biotechnology company representatives. Respondents graded 25 small, mid-size and large CROs across 20 important capabilities that affect provider selection and delivery quality. The report contains 320 pages, including over 300 charts and graphs, and in-depth analysis not previously available to the industry.
This study – designed, executed and analyzed by research professionals from the drug development industry – is a “Consumer Reports”-style guide to buying and delivering quality product development services.
What you will learn:
- Delivery quality for 25 prominent CROs across 20 dimensions of service
- Which CROs deliver consistent service and which are highly variable
- Customer satisfaction and loyalty profiles for each service provider
- What drives sponsors’ selection of CROs for Phase I-IV studies
- Sponsors’ predictions for outsourcing volume, by phase, in the coming 12 months
Report Contents:
- Industry Leaders: This section outlines which service providers are seen as industry leaders, which providers are preferred by sponsors, and which are being used by respondents. These data are split by Phase I, Phase II/III and Phase IIIb/IV services.
- Market Dynamics: This section details sponsors’ reports of outsourcing levels – by phase – for the past 12 months and for the next 12 months.
- Service Provider Selection: This section calls out the important criteria by which sponsor companies select their providers and identifies which CRO attributes are increasing in importance.
- Service Provider Differentiation: provides CROs with sponsor perspectives on various differentiating attributes.
- Service Provider Performance: The lion’s share of the report shines a light on service providers’ delivery quality. Specifically, it showcases providers’ attribute-by-attribute customer quality ratings, service variability and customer loyalty profiles. In addition, this section provides sponsors guidelines for the informed selection of their CROs using certain purchase scenarios.